Schall Law Firm Alerts Immutep Investors to Securities Fraud Class Action on Nasdaq: IMMP
The Schall Law Firm, a Los Angeles-based national shareholder rights litigation firm, is reminding investors of a pending class action lawsuit against Immutep Limited (Nasdaq: IMMP). The suit alleges violations of…
The Schall Law Firm, a Los Angeles-based national shareholder rights litigation firm, is reminding investors of a pending class action lawsuit against Immutep Limited (Nasdaq: IMMP). The suit alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act. Investors who held IMMP shares are being notified of their opportunity to seek appointment as lead plaintiff in the case.
The Allegations
The complaint targets Immutep Limited, a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker IMMP, under two provisions of federal securities law. Section 10(b) of the Securities Exchange Act prohibits fraudulent conduct in connection with the purchase or sale of a security, while Section 20(a) extends potential liability to controlling persons of an entity found to have violated the Act. The Schall Law Firm characterizes the case as a securities fraud action, though the source material does not detail the specific alleged misstatements or omissions at issue.
Lead Plaintiff Role
Investors in Immutep Limited who suffered losses are being alerted to their opportunity to lead the litigation. In class action securities cases, a lead plaintiff is typically the party with the largest financial interest in the relief sought and must also meet adequacy requirements under federal rules. The lead plaintiff role carries the responsibility of directing the litigation strategy and working closely with appointed class counsel. The Schall Law Firm, which brought the reminder notice, describes itself as a national shareholder rights litigation firm.
What Investors Should Know
The announcement from the Schall Law Firm was issued as a press release dated June 29, 2026, from Los Angeles. It does not include specific figures such as a defined class period, alleged share price movements, or a damages estimate — details that typically emerge as litigation develops. Immutep Limited trades on Nasdaq under the symbol IMMP. Investors who believe they may have claims are directed to contact the firm to evaluate their options before any court-imposed deadline in the case.
Related reading
Filed via prnewswire.com